Joost C.M. Uitdehaag, Yvonne G.T.H. van Mil, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Winfried R. Mulder,
Michelle Muller, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Jos de Man, Erik Ensing, Rogier C.
Yvonne G.T.H. van Mil, Joost C.M. Uitdehaag, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Michelle Muller, Winfried R. Mulder, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Jos de Man, Erik Ensing, Rogier
NTRC Therapeutics, a biotech company specialized in the research and development of kinase inhibitors and degraders, will continue under the name Crossfire Oncology.
Founded in 2011 as Netherlands Translational Research Center, NTRC originally pursued a dual business model providing services to
Eget ullamcorper neque sem pellentesque condimentum tellus vulputate sed netus erat lacus proin mauris scelerisque quisque aliquam.
Feugiat venenatis placerat consequat metus eu ornare vitae viverra dui volutpat purus augue blandit amet nunc ut lacinia.